Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Deborah Schrag, MD
|
|
Give Review
Dr. Deborah Schrag works in the field of Oncology. She went to Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a one of the best medicals schools. Columbia University College of Physicians & Surgeons has a rank of 8 in research and a 52 in primary care She received 3 awards: "Regional Top Doctor", "Fellow (FASCO)" and "Super Doctor". Deborah Schrag is a published doctor. She published 45 publications, including: 'Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.' She accepts all Medicare patients.
Publications
- Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer.
- Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.
- Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Variation in breast Cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment.
- Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 Cancer treatment trial.
- Catalog and Comparison of Societal Preferences (Utilities) for Lung Cancer Health States: Results from the Cancer Care Outcomes Research and Surveillance (CanCORS) Study.
- Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness Analysis.
- Incidence of minimally invasive coloRectal cancer surgery at National Comprehensive Cancer Network centers.
- Discussions about clinical trials among patients with newly diagnosed lung and coloRectal cancer.
- Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS).
- Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
- Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III ColoRectal Cancer.
- Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population: Adequate Data Are Neither the Same as Nor the Enemy of Perf...
- Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ.
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma.
- Patient-oncologist cost communication, financial distress, and medication adherence.
- Hospitalization burden and survival among older glioblastoma patients.
- Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced Rectal cancer: a pilot trial.
- Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic ColoRectal Cancer.
- Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions.
- Climate change. What role for short-lived climate pollutants in mitigation policy?
- National trends in pancreatic Cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010.
- Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly ColoRectal and Breast Cancer Patients.
- Secular trends in colon and Rectal cancer relative survival.
- Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of ColoRectal Cancer: American Society of Clinical Oncology Clinical Practice Gu...
- Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.
- Underuse of Hospice Care by Medicaid-Insured Patients With Stage IV Lung Cancer in New York and California.
- Expectations about the effectiveness of radiation therapy among patients with incurable lung Cancer.
- Evolving Role of Neoadjuvant Therapy in Rectal Cancer.
- Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma In Situ.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic ColoRectal Cancer.
- Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung Cancer.
- Stakeholder engagement for comparative effectiveness research in Cancer care: experience of the DEcIDE Cancer Consortium.
- Regional Variation in Spending and Survival for Older Adults With Advanced Cancer.
- Palliative Radiation Therapy Practice in Patients With Metastatic Non-Small-Cell Lung Cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study.
- Feasibility of computer-based self-administered Cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.
- Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network Analysis.
- Measuring coloRectal cancer care quality for the publicly insured in New York State.
- Impact of oncology-related direct-to-consumer advertising: Association with appropriate and inappropriate prescriptions.
- Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic ColoRectal Cancer.
- Religious coping and use of intensive life-prolonging care near death in patients with advanced Cancer.
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.
Schools
Columbia University College Of Physicians and Surgeons
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Fellow (FASCO)
- Super Doctor
Education
-
Brigham and Women's Hospital -
Columbia University College of Physicians & Surgeons
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1922079870 | |
| NPPES Provider LastName | SCHRAG | |
| NPPES Provider FirstName | DEBORAH | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 44.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922079870 |
| Last Name Of The Provider | SCHRAG |
| First Name Of The Provider | DEBORAH |
| View All |
Similar Doctors
|
|
Dr. Joaquim M. Bellmunt, MD |
|
Dr. Philip W. Kantoff, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Justin F. Gainor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Enzinger, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jennifer Gao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreea M. Negroiu, MD
This Doctor is OpenDoctor Recommended.
|